mosaic-nash.tmacademy.orgMOSAIC NASH

Main Navigation Overview Agenda Attendees Speakers Contact us Become a sponsor Access Conference 24 – 25 October, 2024 | Embassy of France, Washington, D. C., USA A Multi-stakeholder Multi-specialty NASH Trialists Think Tank Metabolic, hepatology, nephrology & cardiovascular cross-talk 19 - 20 October, 2023 Georgetown University, Leavey Center, Washington, D. C. ACCESS LIVE STREAM DOWNLOAD AGENDA DOWNLOAD AGENDA Download Virtual Connection Guide Organized by In collaboration Endorsed by the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health A MULTI-STAKEHOLDER MULTI-SPECIALTY NASH/MASH TRIALISTS THINK TANK Metabolic, hepatology, nephrology & cardiovascular cross-talk Download Agenda Organized by In collaboration with Endorsed by the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health A MULTI-STAKEHOLDER MULTI-SPECIALTY NASH TRIALISTS THINK TANK Metabolic, hepatology, nephrology & cardiovascular cross-talk 19 - 20 October, 2023 Embassy of France, 4101 Reservoir Road, NW - Washington, D.C. - 20007 Download Agenda Download Agenda Organized by In collaboration Endorsed by the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health A MULTI-STAKEHOLDER MULTI-SPECIALTY NASH TRIALISTS THINK TANK 19 – 20 October, 2023 Embassy of France 4101 Reservoir Road, NW – Washington, D.C. – 20007 Download Agenda Organized by In collaboration Endorsed by the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health A MULTI-STAKEHOLDER MULTI-SPECIALTY NASH/MASH TRIALISTS THINK TANK Metabolic, hepatology, nephrology & cardiovascular cross-talk Download Agenda Organized by In collaboration with Endorsed by the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health Overview Topics Speakers Learning Objectives Agenda Sponsors Overview MOSAIC - Global NASH/MASH Trialist Forum brings together cardiology, endocrinology & hepatology clinical trialists, industry, regulatory experts, payers, patients representatives and other stakeholders to further advance collective intelligence and foster collaboration about clinical trials through cross-talks. Special Announcement It is with deep sadness that the MOSAIC team learned of the passing of Prof Stephen Harrison on 4/24/2024. Prof. Harrison was one of the key members in the MOSAIC project and will be greatly missed for his commitment to a multi organ and multi disciplinary approach to MASH/ MAFLD. MOSAIC - the 1st Global NASH Trialist Forum will bring together cardiology, endocrinology & hepatology clinical trialists, industry, regulatory experts, payers, patients representatives and other stakeholders to further advance collective intelligence and foster collaboration about NASH diagnosis and management. NASH/MASH: a major unmet need in clinical trial science it is now clear that non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH/MASH) are a public health problem worldwide. • It affects around 25-30% of the adult population and causes considerable liver-related and extra-hepatic morbidity and mortality. • NASH/MASH is considered a metabolic and multi organ disease with cardiovascular complications, worsening metabolic dysfunction and other extra-hepatic diseases, such as type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), or certain extra-hepatic cancers. Learning Objectives Why should you attend? Networking opportunities Think Tank focused Workshops Latest trials updates Patient participation View more Chairs Javed Butler USA Stephen Harrison USA Veronica Miller USA Arun Sanyal USA Faiez Zannad France × Register Country Afghanistan Albania Algeria Andorra Angola Antigua & Deps Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bhutan Bolivia Bosnia Herzegovina Botswana Brazil Brunei Bulgaria Burkina Burundi Cambodia Cameroon Canada Cape Verde Central African Rep Chad Chile China Colombia Comoros Congo Congo {Democratic Rep} Costa Rica Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Greece Grenada Guatemala Guinea Guinea-Bissau Guyana Haiti Honduras Hungary Iceland India Indonesia Iran Iraq Ireland {Republic} Israel Italy Ivory Coast Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea North Korea South Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Micronesia Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar, {Burma} Namibia Nauru Nepal Netherlands New Zealand Nicaragua Niger Nigeria Norway Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Qatar Romania Russian Federation Rwanda St Kitts & Nevis St Lucia Saint Vincent & the Grenadines Samoa San Marino Sao Tome & Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Sudan Spain Sri Lanka Sudan Suriname Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Togo Tonga Trinidad & Tobago Tunisia Turkey Turkmenistan Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Yemen Zambia Zimbabwe Professional activity / medical speciality Cardiology Internal medicine Endocrinology / Diabetology Nephrology General medicine Nursing Student / Physician in training Industry Other By clicking the button, you agree to SGLT2 terms of service and privacy policy. See all Speakers Topics NASH/MASH – Cardiovascular intersections Epidemiology, disease mechanisms Non-invasive Tests (NITs) Trial design issues and innovations Patient population selection in NASH/MASH trials Download agendaView full agenda Endpoints Pathways to approval Therapeutics Experiences and case studies Download agendaView full agenda Topics NASH – Cardiovascular Intersection Epidemiology, disease mechanisms NonInvasive Tests (NITs) Trial design issues and innovations Patient population selection in NASH trials Endpoints Pathways to approval Therapeutics Experiences and case studies Download agendaView full agenda Sponsors We would like to thank the companies that support the organisation of this program. Become a sponsor Silver Sponsors | Gold Sponsors Silver Sponsors Bronze Sponsors Preference Sponsors Support Sponsors Gold Sponsors Silver Sponsors Bronze Sponsors Preference Sponsors Support Sponsors Bronze Sponsors Supporter Sponsors | Supporter Sponsors Silver Sponsors Silver Sponsors Bronze Sponsors Bronze Sponsors Supporter Sponsors Supporter Sponsors Become a sponsor In collaboration with the Liver forum of the Conditions of Use Privacy Policy Legal Notice Cookie Settings Contact In collaboration with the Liver forum of the Conditions of use | Privacy Policy | Legal Notice | Cookie Settings | Contact Copyright © 2024 All Rights Reserved. Powered by Beyond Technologies. Proudly powered by WordPress | Theme: Mosaic Child by understrap.com .(Version: 1.1.0) We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. Cookie Settings Accept All Reject All Manage consent Close Privacy Overview This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on . Necessary Necessary Always Enabled Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Cookie Duration Description cookielawinfo-checkbox-analytics 11 months This...